To determine 1) whether the effect of intravenous nitroglycerin (NG) therapy during acute myocardial infarction on creatine kinase infarct size is influenced by infarct location (anterior vs. 
The combined results of four randomized clinical studies3-6 suggest that the beneficial effect on infarct size might depend on the timing of therapy and infarct location. [3] [4] [5] [6] Experimental studies suggest that the dose might be of critical importance.78 Thus, intravenous NG therapy in low dose during the first 6 hours after coronary artery ligation reduced the size ofboth inferior7 and anterior8 infarcts, but the beneficial effects on infarct size and collateral flow were abolished when hypotension was induced by higher doses of NG. 8 An additional benefit of low-dose NG therapy over the first 6 hours of AMI in the canine model was a decrease of infarct expansion at 7 days. 9 Despite encouraging findings in the clinical studies, such as decreased left ventricular (LV) filling pressure,356 improved global LV function,36 decreased electrocardiographic ST-segment elevation,3'6 decreased creatine kinase (CK) infarct size,3,4,6 persistently decreased endocardial surface area of LV asynergy on serial two-dimensional echocardiography,6 and improved perfusion and defect scores on thallium scintigraphy,5 the use of intravenous NG therapy in AMI for myocardial salvage has not gained general acceptance. This hesitation might be partly attributable to the lack of clear demonstration of benefit in all clinical studies, fear of NG-induced hypotension in AMI, and lack of simple guidelines for titrating the dose. Thus, Jaffe et a14 treated patients within 10 hours of onset of pain and found benefit only in inferior infarcts. Bussmann et a13 found benefit with therapy begun before and after 8 hours of onset of pain in anterior and inferior AMI. Flaherty et a15 did not find differences between NG and placebo groups, but retrospective analysis suggested benefit in patients given NG within 10 hours of onset of pain, especially those with inferior AMI. We6 reported benefit with NG therapy 5.9 hours (range, 4-6 hours) of onset of anterior transmural AMI. Although there is agreement that the dose should be low, various titration endpoints were used: 1) a 10-30% decrease in LV filling pressure The control patients were given 5% dextrose in water intravenously without NG at a constant rate of 1 ml/min as placebo for the 48 hours.
Measurements
During the first 48 hours, all patients had the following parameters recorded at least twice over 0.5 hours before the treatments, repeated serially during the treatments (1-4/hr over the first 12 hours and 4-12/hr over the next 36 hours) and at 1 hour after treatments were stopped: heart rate, blood pressure (by sphygmomanometer), CK activity, and two-dimensional echocardiography studies for LV asynergy,615 for volume and ejection fraction,6'15,16 and for indexes of expansion. 12'13 The twodimensional echocardiography studies were repeated on days 4, 6, 8, and 10 and at predischarge. All patients had continuous electrocardiographic monitoring for the first 48 hours or more. Additional data, during the infusions and the subsequent interval to day 10 and predischarge, were collected on all complications and all other drugs or therapies used. Where close hemodynamic monitoring was clinically indicated (48 patients: 19 NG; 29 controls), arterial lines (for blood pressure) and thermodilution flotation catheters (for pulmonary capillary wedge pressure, right heart pressures, and cardiac output) were used. Blood samples for total CK activity were drawn in all patients before the infusions and at 2-4 hour intervals during the infusions for up to 48 hours or more until baseline levels were reached. Total CK activity values were used to compute CK-infarct size in gram-equivalents (Model 9874A, Hewlett-Packard), as described previously.6 CK-MB could not be measured on all patients.
Complete two-dimensional echocardiographic recordings (Diasonics V3400R phased-array ultrasonograph) were made in all patients6 with adequate visualization of the four cardiac chambers and ventricular walls. Standard two-dimensional echocardiographic views including parastemal long-axis, four short-axis (at mitral, chordal, midpapilary, and low papillary levels), and apical four-and two-chamber, were videotaped systematically for review in realtime, slow-motion, and single-frame format. The positions ofthe patients and transducer were noted for use in serial studies, as described previously.6,15
All patients were followed for at least 12 months for complications, cardiovascular events, and functional class as per questionnaire. Data collected at different stages of the study were coded (i.e., blinded for patient identity and grouping) by a nursetechnician. These codes were not broken until all data collection and analyses were completed. Members of the investigative team were not involved in the care of the patients. Other drugs or therapies were not manipulated.
The clinical syndrome of infarct expansion2,9-13 was diagnosed in patients who developed a second acute event after 48 hours of AMI associated with 1) acute hypotension (systolic blood pressure <90 mm Hg and peripheral hypoperfusion), LV failure with pulmonary congestion, evidence of LV dilatation, with or without further chest pain, no significant new ECG changes of injury, no significant new plasma CK elevation (<100 IU/l) suggesting new necrosis, and 2) two-dimensional echocardiographic evidence of regional diastolic stretching (>25% increase in asynergy-containing endocardial segment length), thinning (>25% decrease in thickness of the asynergic segment), and dilatation (>25% increase in dimension) compared with the initial two-dimensional echocardiographic study. Analysis of Two-dimensional Echocardiographic Data Coded recordings (tape and log numbers) were analyzed separately in three steps by two observers, with no knowledge of patient identity or grouping. Three serial two-dimensional echocardiographic recordings from 12 normal subjects (athletes with normal histories, electrocardiogram, and exercise stress test) were also coded and analyzed with the study patients. Differences were resolved by consensus. Interobserver error in measurements was small (less than 1% in marking asynergy, segment length, and wall thickness; less than 4% in areas of outlines). First, endocardial and epicardial LV outlines were traced on plastic overlays from electrocardiogram-gated images frozen at end diastole and end systole and modified on multiple playbacks. Special attention was given to anatomic landmarks (papillary muscle markings; right ventricular and LV junctions) and shape. Second, markings of the extent of LV asynergy, defined as akinesis (no systolic inward motion and thickening) or dyskinesis (systolic outward motion and thinning) or both were made on each LV endocardial diastolic outline by careful visual assessment of wall motion and thickening on repeated real-time video playbacks, as reported from this laboratory.6'15 Care was taken to ensure that asynergic segments did not show systolic inward endocardial motion and thickening by comparing wall thicknesses in systole and diastole (light-pen system) and comparing aligned diastolic outlines.615'17 The endocardial diastolic outlines and asynergic segments were then digitized (Models 9874A and 9835A, HewlettPackard) for computing the circumferential and angular extents of asynergy in each short-axis section as percent, as well as the total extent of LV asynergy as percent surface area of the endocardial shell, with the apical four-chamber and four serial short-axis data as described previously.615 Because regional shape distortion was present in the asynergic zones on diastolic outlines in patients with Q wave infarction, the "ideal" asynergic segment corresponding to the angular extent of "actual" asynergy was used to compute total LV asynergy and avoid overestimation.18"19 Global ejection fractions were calculated from LV end-diastolic and end-systolic volumes that were computed from outlines of two long-axis views (apical four-and twochamber) and four short-axis views with the modified Simpson's rule.6, 15, 16 Third, topographic measurements were made on end-diastolic outlines of short-axis images at the mid-LV or papillary level.12 Expansion index was computed as the ratio of the asynergy containing endocardial segment length to that of the nonasynergy containing endocardial segment length.6'12"13 Thinning ratio was computed as the ratio of the average thickness of the asynergic zone to the average thickness of the nonasynergic zone. 6, 12 Statistics All data collected and coded during the study were analyzed at the end in double-blind fashion, with no knowledge of patient identity or grouping. Statistical analysis was based on intention to treat. The following methods were used: 1) analysis of variance (ANOVA) for the significance of difference within a group and multivariate ANOVA for the significance between groups, 2) the x2 test (with ANOVA) to assess the significance of difference in event frequency between groups, and 3) repeated measures ANOVA for comparing serial data in each group. Results are given as mean ± SD. Differences were assumed significant for psO.05.
Results The NG group (n = 154) and the control group (n= 156) were well matched for clinical and laboratory parameters on admission (Table 1) . In all, 87% of the patients had transmural or Q wave infarcts (Q waves >40 msec wide and >0.2 mV deep), 79% had first infarcts, 45% had anterior infarcts, and 36% were hypertensive on admission (60 NG and 51 controls). The infusions were begun within 4 hours of the onset of pain in 22% of the patients, within 6 hours in 43%, and within 10 hours in 73%. The distribution of patients in the different Killip classes on admission were similar for the NG group (I, 72; II, 58; III, 24) and the control group (I, 71; II, 58; III, 27).
In the NG group, the average infusion rate was 45±34 jug/min (range, 4-192 (Figure 2 ). The decrease in CKinfarct size with NG was greater in early than in late subgroups (Table 2) . Thus, the decrease in the early and late subgroups based on the 4-hour cutoff were 43% versus 22%, but this benefit was still found in the early subgroups with a 10-hour cutoff, the percent decrease being 32% versus 19% (Table 2) . Figure 3 for the 128 patients (61 NG and 67 controls) with adequate repeated two-dimensional echocardiographic recordings for this detailed analysis and no past history or evidence of old acute myocardial infarction. In the NG group, LV asynergy decreased promptly and was still 34% below baseline at 6 hours (28 + 8% vs. 18 + 8%, p<0.001) and 43% below baseline at 10 days (28 + 8% vs. 16 + 8%, p<0.001). There was a parallel increase in LV ejection frac- The initial and final data on expansion index and thinning ratio for the 128 patients are summarized in Figure 5 . There was more expansion and thinning in the controls than the NG group. This effect was found for both anterior and inferior infarct subgroups. The percent change in thickness of the infarct segment was greater in controls than the NG groups ( -17 + 11% vs. 4 + 9%, p<0.001). The effect of NG on expansion index and thinning ratio was not significantly influenced by timing of therapy within 4 or 10 hours. Thus, over the first 10 days, the percent change in expansion indexes in the NG subgroups were -3% versus -1% with a 4-hour cutoff and -1% versus -1% with a 10-hour cutoff; the percent change in thinning ratios were -2% versus -6% with a 4-hour cutoff and -2 versus -3% with a 10-hour cutoff.
In-hospital Follow-up and Complications
The duration of hospitalization ranged from 9 to 38 days, with over 95% survivors being discharged 10 days (range, 9-12 days) after admission. The Killip class scores over the 10 days were significantly less (p<0.05) in the NG than in the control group ( Figure 6 ). The majority of infarct-related complications were less frequent in the NG than in In Table 5 , an equal number of patients in both groups needed NG after 48 hours in the form of oral isosorbide dinitrate or nitropaste for recurrent chest pain (42% vs. 44%) and indomethacin or ibuprofen therapy for pericarditis (23% vs. 21%). Betablockers and calcium blockers had been used more frequently in the acute phase in inferior controls.
The clinical characteristics of infarct expanders were similar for the control (n = 24) and NG (n = 3) groups. In both groups, the expanders tended to have anterior infarcts (63% vs. 67%), MAP more than 80 mm Hg (58% vs. 100%), Q wave infarcts (92% vs. 100%), large CK-infarct sizes (68 vs. 46 geq), moderate initial LV asynergy (29% vs. 32%), received therapy later (71% vs. 66% after 4 hours), and treatment with indomethacin or ibuprofen for pericarditis (29% vs. 100%).
Follow-up and Mortality
The final follow-up of survivors ranged from 29 to 68 months (mean, 43 months or 186 weeks). Mortality was less in the NG group than the control group at 7 days (5% vs. 19%, p<0.0005), 15 shown in the actuarial survival curves ( Figure 7) . As for in-hospital deaths, this benefit was mainly in those with Q wave infarction. On the late follow-up, more of the survivors in the control group required therapy for cardiac failure ( First, the beneficial effect of NG therapy on CK-infarct size was critically dependent on early timing and dosage but not on infarct location. The beneficial effect on CK-infarct size was most marked when therapy was begun less than 4 hours from the onset of pain, but significant benefit was still present in patients treated up to 10 hours from the onset of pain. Also, NG therapy was beneficial in both Q wave and non-Q wave infarction. However, the benefit was less in the few patients (9%) whose MBP drifted below 80 mm Hg within the first 12 hours of the NG infusion.
Second, the overall beneficial effect of NG therapy on CK-infarct size was associated with improved LV hemodynamics and two-dimensional echocardiographic indexes of LV regional contractile and global systolic function. Thus, compared with controls, 1) the MBP averaged 8% less and the ratepressure product 6% less over the first 10 hours with NG: 2) the clinical Killip class score with NG was 40% less at 24 hours, 58% less at 48 hours, and 41% less at 10 days; 3) among patients in whom flotation catheters were inserted (15%), pulmonary capillary wedge pressure throughout the infusions was 30% less and cardiac index between 24 and 48 hours was 15% more with NG; and 4) in the patients with adequate serial two-dimensional echocardiographic data (4 1%), LV asynergy decreased promptly and ejection fraction increased promptly with NG (these differences persisted at 10 days as well as at 3 and 6 months); LV asynergy was 29% less at 6 hours, 29% less at 48 hours, and 40% less at 10 days; and LV ejection fraction was 40% more at 6 hours, 28% more at 48 hours, and 22% more at 10 days. Although the effects of NG on all these parameters were not significantly dilferent for anterior and inferior infarcts, improvement in LV asynergy, LV ejection fraction, and Killip class by 24 and 48 hours tended to be greater in early than in late subgroups. The negative effect of NG-induced hypotension with MBP below 80 mm Hg in the first 12 hours was also seen with the other indexes of infarct size, statistically significant with LV asynergy, and not significant with LV ejection fraction.
Third, infarct expansion and thinning, from serial two-dimensional echocardiographic data in 128 patients, were less in the NG group than in controls. The expansion index increased by 14% at 2-3 days and 31% at 7-10 days in controls but did not change with NG. The thinning ratio decreased by 6% at 2-3 days and 17% at 7-10 days in controls but did not change with NG. The infarct-containing segment lengths were longer, and thicknesses of the infarct segments were less in controls than the NG group; the changes in these measurements followed closely those in expansion index and thinning ratio. Thus, the beneficial effect of NG on limiting infarct expansion was already apparent during the first 2-3 days, suggesting early remodeling. This is supported by the finding that the LV end-diastolic internal dimension was 14% less at 48 hours and 5% less at 10 days with NG compared with controls.
Fourth, the frequency of major infarct-related complications and deaths were significantly lower in the NG group. Thus, comparing the NG group with controls, the percent reduction in frequency of the complications were 87% for the infarct expansion syndrome (p<0.0005), 77% for LV thrombus on two-dimensional echocardiography (p<0.0005), 67% for cardiogenic shock (p<0.005), and 50% for infarct extension (p<0.025) and all in-hospital deaths up to 38 days (p<0.01). The percent reduction in frequency of deaths at specific time intervals were 74% by 7 days (p<0.0005), 59% by 15 days (p<0.005), 46% by 1 month (p<0.005), 43% by 3 months (p<0.025), 36% by 6 months (p<0.05), 32% by 12 months (p<0.05), and 28% by 43 months (p<O. 10). However, this beneficial effect on survival was only seen with anterior infarcts.
Other studies have emphasized low dosage and early timing of NG therapy. Bussmann et a13 reported a 30% reduction in CK-infarct size with therapy within 8 hours of onset of pain in nine patients. Jaffe et a14 reported a 36% decrease in CK-infarct size in the inferior subgroup (but not anterior) given therapy within 10 hours of onset of pain. Flaherty et a15 found no decrease in infarct size but commented on the greater benefit in patients treated within 10 hours of onset of pain. The benefit with NG beyond 4 hours and up to 10 hours of onset of pain in this and reported studies3-5 might be attributable to a delayed march to necrosis and gradual "reperfusion" via collateral channels opened by NG 12 hours. This effect of NG on CK-infarct size was associated with decreased LV asynergy and improved LV ejection fraction on two-dimensional echocardiography, improved LV hemodynamics, and improved clinical Killip scores. In addition, NG therapy improved LV topography with no increase in infarct expansion index, no decrease in infarct thinning ratio, and decreased LV internal diastolic dimension on two-dimensional echocardiography. More important, NG therapy markedly reduced the frequency of infarct-related in-hospital complications such as the clinical infarct expansion syndrome, infarct extension, cardiogenic shock, deaths, and LV thrombus on two-dimensional echocardiography. Finally, NG therapy decreased mortality up to 12 months, but this effect was found only with anterior Q wave infarction. Thus, low-dose intravenous NG therapy should be considered for myocardial salvage and limitation of infarct expansion.
